Objectives Yet endometrial cancer survival rates, cancer progression and risk of death with this cause have not been studied in Georgia. Conducting the study based on population registry data has been possible since 2015. 5 years registry dBase allowed us to study 3 years survival and risks. Methods 1,800 (6.1%) cases of endometrial cancer were registered in the Georgia in 2015-2019. Using dBase SPSS of the registry, 3-year survival of endometrial cancer and risks of cancer progression were studied; Risks of cancer progression and death were assessed 36 months after the incidence. Results Average 3-year survival of endometrial cancer in Georgia made up 75.0%, in Tbilisi -78.2%. Risk of endometrial cancer progression 36 months after the incidence was 4.5% in Georgia and 6.3% in Tbilisi. The risk of endometrial cancer progression in Tbilisi is 1.9 times higher compared to the regions of Georgia. This is probably due to the high incidence of endometrial cancer in Tbilisi. Among gynecological cancer sites endometrial cancer ranks 1st in Tbilisi. Conclusions Research should be continued and study 5 years survival and risks of cancer progression and death, according to its treatment methods and schemes, as well as cytological, ultrasound (3D), hysteroscopy, histological, histochemical and molecular characteristics of cancer. Study of 5-year survival, in addition should determine ECOG Adjusted Survival, for which it is recommended that the Registry add ECOG follow-up to the registration variables. The latter will give us an additional opportunity to assess the cancer burden with both DALYs and QALYs index.
Methods Pubmed, EMBASE, Medline and the Cochrane Database were searched from inception to March 2022. Inclusion criteria were studies assessing the treatment of LGSC with a MEKi in the primary or recurrent setting, published in English. Case reports, case series, conference proceedings, in vitro studies and animal studies were excluded. Studies were screened and assessed for eligibility by two independent reviewers (AK, CC), with conflicts resolved by a third reviewer (TZ). Data was extracted using pre-established criteria.Results Initial literature search identified 1815 papers; four met eligibility criteria. Three were randomized clinical trials and one was a phase II single-arm prospective cohort study. A total of 680 patients were included, of which 416 were treated with a MEKi alone. All patients were treated for recurrent LGSOC. ORR ranged from 12.1 to 26% and median progression-free survival (PFS) ranged from 7.2 to 13 months.Conclusions While one study demonstrated significantly improved efficacy of MEKi over physician-choice systemic therapy, another did not show benefit. Two additional studies did not compare MEKi to traditional therapies, limiting their clinical relevance. LGSC with BRAF and KRAF mutations have higher ORR to MEKi. Further prospective and randomized trials are needed to determine the efficacy of MEKi in treating LGSC.
Studies assessing cancer patients' needs have revealed that 32% of patients diagnosed with cancer clearly state the need for psychosocial rehabilitation services.The present study aims to assess the psychosocial state of women after breast cancer surgery in Georgia, identify the challenges in the accessibility of full-value services, and facilitate the formation of an evidence-based best practice policy. 360 women, after breast cancer surgery, have participated in the study, among them, 180 women have received psychosocial rehabilitation training (main group), and 180 women (control group) have not used such service. The need for post-treatment psychological rehabilitation was reported by 93% of the main group respondents that is 30% more than the result for the same question in the control group.The same is confirmed by the survey of medical staff - 97%. It is noteworthy that 80% of interviewed medical staff believe that psychosocial rehabilitation is as important as other treatment.The majority of interviewed respondents in both groups (main group – 57.2%,control group – 64%) speak about a financial burden.The study has also revealed a low awareness both in cancer patients and medical staff. Among the interviewed medical staff, 60 % have no information about the rehabilitation services available in Georgia.
BRCA 1/2 germline mutations. Oncological counseling is essential to ensure an appropriate interpretation of the genetic test result, explain the management possibilities, helping people in the choices of medical options. Mutations of the BRCA 1 and BRCA 2 genes increase the risk of developing familial breast and ovarian cancer. Prevention options we can offer to BRCA mutated patients are intensified surveillance, chemoprevention and prophylactic surgery regarding breast and ovarian cancer. Methods A 35-item questionnaire on the type of prevention choice made was developed and offered to 197 BRCA mutated patients of the Sant 'Anna Hospital in Turin from September 2018 to February 2021. We selected 61 patients who correctly completed the questionnaire. Results Concerning breast cancer risk reduction, 63% of patients tell us that the preferred option is intensified breast surveillance while for the ovary, the preferred option is surgery in 50% of patients. In both cases the variable 'desire for motherhood' influenced the patient' choices in an important way. The 90% of women were satisfied with the doctor's help in directing their choice of prevention. Conclusions Physicians should discuss the advantages and disadvantages of risk reduction strategies with high-risk women. Concerning ovarian surgery, surgical menopause and estrogen deprivation are two aspects to consider and to inform patients about symptoms and their treatment. From the point of view of breast surgery, it is considered appreciable talk about aesthetic outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.